Blood biomarkers role in acute ischemic stroke patients: higher is worse or better?

Research output: Contribution to journalArticle

Standard

Blood biomarkers role in acute ischemic stroke patients : higher is worse or better? / Kisialiou, Aliaksei; Pelone, Giordana; Carrizzo, Albino; Grillea, Giovanni; Trimarco, Valentina; Marino, Marina; Bartolo, Michelangelo; De Nunzio, Alessandro Marco; Grella, Rodolfo; Landolfi, Alessandro; Puca, Annibale; Colonnese, Claudio; Vecchione, Carmine.

In: Immunity & Ageing, Vol. 9, No. 1, 22, 31.10.2012.

Research output: Contribution to journalArticle

Harvard

Kisialiou, A, Pelone, G, Carrizzo, A, Grillea, G, Trimarco, V, Marino, M, Bartolo, M, De Nunzio, AM, Grella, R, Landolfi, A, Puca, A, Colonnese, C & Vecchione, C 2012, 'Blood biomarkers role in acute ischemic stroke patients: higher is worse or better?', Immunity & Ageing, vol. 9, no. 1, 22. https://doi.org/10.1186/1742-4933-9-22

APA

Kisialiou, A., Pelone, G., Carrizzo, A., Grillea, G., Trimarco, V., Marino, M., Bartolo, M., De Nunzio, A. M., Grella, R., Landolfi, A., Puca, A., Colonnese, C., & Vecchione, C. (2012). Blood biomarkers role in acute ischemic stroke patients: higher is worse or better? Immunity & Ageing, 9(1), [22]. https://doi.org/10.1186/1742-4933-9-22

Vancouver

Kisialiou A, Pelone G, Carrizzo A, Grillea G, Trimarco V, Marino M et al. Blood biomarkers role in acute ischemic stroke patients: higher is worse or better? Immunity & Ageing. 2012 Oct 31;9(1). 22. https://doi.org/10.1186/1742-4933-9-22

Author

Kisialiou, Aliaksei ; Pelone, Giordana ; Carrizzo, Albino ; Grillea, Giovanni ; Trimarco, Valentina ; Marino, Marina ; Bartolo, Michelangelo ; De Nunzio, Alessandro Marco ; Grella, Rodolfo ; Landolfi, Alessandro ; Puca, Annibale ; Colonnese, Claudio ; Vecchione, Carmine. / Blood biomarkers role in acute ischemic stroke patients : higher is worse or better?. In: Immunity & Ageing. 2012 ; Vol. 9, No. 1.

Bibtex

@article{3ff154eeea59473cb3355487884ac583,
title = "Blood biomarkers role in acute ischemic stroke patients: higher is worse or better?",
abstract = "UNLABELLED: BACKGROUND: Thrombolytic therapy (TT) for acute ischemic stroke (AIS) can provoke bleeding's complication depending on the ischemic lesion (IL) dimension. Inflammation involved in the setting of acute ischaemic stroke, is associated with infarct size. We aimed to study the independent correlation and association between clinical panel of routinely identified biomarkers, including inflammatory parameters, and cerebral IL dimension and site.RESULTS: We evaluated eleven biomarkers in 105 unrelated patients during their hospitalization after acute stroke event. Our data indicate a significant association of: a) confluent IL size with 4th quartile of Erythrocyte Sedimentation Rate (ESR) (OR = 5.250; 95% CI, 1.002 to 27.514) and an independent correlation with sex; b) confluent IL size with 3rd quartile of fibrinogen (OR = 5.5; 95% CI, 1.027 to 29.451); c) confluent IL size with 3rd quartile of platelets (OR= 0.059; 95% CI, 0.003 to 1.175) and independent correlation with sex; d) smaller IL size (OR = 5.25; 95% CI, 1.351 to 20.396) with 3rd quartile of albumin levels and nodular and parenchimal IL size with 2nd (OR = 0.227; 95% CI, 0.053 to 0.981), 3rd (OR = 0.164; 95% CI, 0.038 to 0.711) and 4th (OR = 0.205; 95% CI, 0.048 to 0.870) quartiles albumin levels; e) smaller IL size with 3rd quartile triglycerides (TG) levels (OR = 9; 95% CI, 2.487 to 32.567) and an independent correlation with anterior location. Smaller IL size, anterior AIS turned out to be independently correlated with high serum albumin levels. Finally, high INR and PTT values were associated with worse NIHSS clinical outcomes in contrast to that observed with higher albumin level.CONCLUSIONS: We provide evidence of routine biomarkers levels correlation with acute IL size, independently of age and sex. In addition, we highlight the importance of differentiation of biomarkers normal interval levels for further improvement not only of the clinical decision making but also in post-acute clinical outcome management.",
keywords = "Journal Article",
author = "Aliaksei Kisialiou and Giordana Pelone and Albino Carrizzo and Giovanni Grillea and Valentina Trimarco and Marina Marino and Michelangelo Bartolo and {De Nunzio}, {Alessandro Marco} and Rodolfo Grella and Alessandro Landolfi and Annibale Puca and Claudio Colonnese and Carmine Vecchione",
year = "2012",
month = oct,
day = "31",
doi = "10.1186/1742-4933-9-22",
language = "English",
volume = "9",
journal = "Immunity & Ageing",
issn = "1742-4933",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Blood biomarkers role in acute ischemic stroke patients

T2 - higher is worse or better?

AU - Kisialiou, Aliaksei

AU - Pelone, Giordana

AU - Carrizzo, Albino

AU - Grillea, Giovanni

AU - Trimarco, Valentina

AU - Marino, Marina

AU - Bartolo, Michelangelo

AU - De Nunzio, Alessandro Marco

AU - Grella, Rodolfo

AU - Landolfi, Alessandro

AU - Puca, Annibale

AU - Colonnese, Claudio

AU - Vecchione, Carmine

PY - 2012/10/31

Y1 - 2012/10/31

N2 - UNLABELLED: BACKGROUND: Thrombolytic therapy (TT) for acute ischemic stroke (AIS) can provoke bleeding's complication depending on the ischemic lesion (IL) dimension. Inflammation involved in the setting of acute ischaemic stroke, is associated with infarct size. We aimed to study the independent correlation and association between clinical panel of routinely identified biomarkers, including inflammatory parameters, and cerebral IL dimension and site.RESULTS: We evaluated eleven biomarkers in 105 unrelated patients during their hospitalization after acute stroke event. Our data indicate a significant association of: a) confluent IL size with 4th quartile of Erythrocyte Sedimentation Rate (ESR) (OR = 5.250; 95% CI, 1.002 to 27.514) and an independent correlation with sex; b) confluent IL size with 3rd quartile of fibrinogen (OR = 5.5; 95% CI, 1.027 to 29.451); c) confluent IL size with 3rd quartile of platelets (OR= 0.059; 95% CI, 0.003 to 1.175) and independent correlation with sex; d) smaller IL size (OR = 5.25; 95% CI, 1.351 to 20.396) with 3rd quartile of albumin levels and nodular and parenchimal IL size with 2nd (OR = 0.227; 95% CI, 0.053 to 0.981), 3rd (OR = 0.164; 95% CI, 0.038 to 0.711) and 4th (OR = 0.205; 95% CI, 0.048 to 0.870) quartiles albumin levels; e) smaller IL size with 3rd quartile triglycerides (TG) levels (OR = 9; 95% CI, 2.487 to 32.567) and an independent correlation with anterior location. Smaller IL size, anterior AIS turned out to be independently correlated with high serum albumin levels. Finally, high INR and PTT values were associated with worse NIHSS clinical outcomes in contrast to that observed with higher albumin level.CONCLUSIONS: We provide evidence of routine biomarkers levels correlation with acute IL size, independently of age and sex. In addition, we highlight the importance of differentiation of biomarkers normal interval levels for further improvement not only of the clinical decision making but also in post-acute clinical outcome management.

AB - UNLABELLED: BACKGROUND: Thrombolytic therapy (TT) for acute ischemic stroke (AIS) can provoke bleeding's complication depending on the ischemic lesion (IL) dimension. Inflammation involved in the setting of acute ischaemic stroke, is associated with infarct size. We aimed to study the independent correlation and association between clinical panel of routinely identified biomarkers, including inflammatory parameters, and cerebral IL dimension and site.RESULTS: We evaluated eleven biomarkers in 105 unrelated patients during their hospitalization after acute stroke event. Our data indicate a significant association of: a) confluent IL size with 4th quartile of Erythrocyte Sedimentation Rate (ESR) (OR = 5.250; 95% CI, 1.002 to 27.514) and an independent correlation with sex; b) confluent IL size with 3rd quartile of fibrinogen (OR = 5.5; 95% CI, 1.027 to 29.451); c) confluent IL size with 3rd quartile of platelets (OR= 0.059; 95% CI, 0.003 to 1.175) and independent correlation with sex; d) smaller IL size (OR = 5.25; 95% CI, 1.351 to 20.396) with 3rd quartile of albumin levels and nodular and parenchimal IL size with 2nd (OR = 0.227; 95% CI, 0.053 to 0.981), 3rd (OR = 0.164; 95% CI, 0.038 to 0.711) and 4th (OR = 0.205; 95% CI, 0.048 to 0.870) quartiles albumin levels; e) smaller IL size with 3rd quartile triglycerides (TG) levels (OR = 9; 95% CI, 2.487 to 32.567) and an independent correlation with anterior location. Smaller IL size, anterior AIS turned out to be independently correlated with high serum albumin levels. Finally, high INR and PTT values were associated with worse NIHSS clinical outcomes in contrast to that observed with higher albumin level.CONCLUSIONS: We provide evidence of routine biomarkers levels correlation with acute IL size, independently of age and sex. In addition, we highlight the importance of differentiation of biomarkers normal interval levels for further improvement not only of the clinical decision making but also in post-acute clinical outcome management.

KW - Journal Article

U2 - 10.1186/1742-4933-9-22

DO - 10.1186/1742-4933-9-22

M3 - Article

C2 - 23110752

VL - 9

JO - Immunity & Ageing

JF - Immunity & Ageing

SN - 1742-4933

IS - 1

M1 - 22

ER -